Article
Oncology
Leonie Smeenk, Sophie Ottema, Roger Mulet-Lazaro, Anja Ebert, Marije Havermans, Andrea Arricibita Varea, Michaela Fellner, Dorien Pastoors, Stanley van Herk, Claudia Erpelinck-Verschueren, Tim Grob, Remco M. Hoogenboezem, Francois G. Kavelaars, Daniel R. Matson, Emery H. Bresnick, Eric M. Bindels, Alex Kentsis, Johannes Zuber, Ruud Delwel
Summary: Research identifies MYB transcription factor-driven EVI1 expression as a critical target for therapy in acute myeloid leukemia. Interference with MYB activity leads to downregulation of EVI1 expression in the GATA2 enhancer, inducing abnormal cell differentiation and death.
Article
Oncology
Anna Aakula, Aleksi Isomursu, Christian Rupp, Andrew Erickson, Nikhil Gupta, Otto Kauko, Pragya Shah, Artur Padzik, Yuba Raj Pokharel, Amanpreet Kaur, Song-Ping Li, Lloyd Trotman, Pekka Taimen, Antti Rannikko, Jan Lammerding, Ilkka Paatero, Tuomas Mirtti, Johanna Ivaska, Jukka Westermarck
Summary: This study found that prostate cancer tumors with concomitant inhibition of PP2A and PTEN are particularly aggressive, with low patient survival rates. Overexpression of PME-1 inhibits anoikis in PTEN-deficient prostate cancer cells. The results suggest that PME-1 may be a candidate biomarker for particularly aggressive PTEN-deficient prostate cancer.
MOLECULAR ONCOLOGY
(2023)
Article
Oncology
Jin-Ock Kim, Kwang-Hyeok Kim, Eun Ji Baek, Bomi Park, Min Kyung So, Byoung Joon Ko, Han-Jik Ko, Sang Gyu Park
Summary: The study developed an anti-c-Kit antibody-drug conjugate, NN2101-DM1, which showed potent growth-inhibitory activities against c-Kit-positive cancer cell lines, especially in cases of TKI resistance. In mouse xenograft models, NN2101-DM1 exhibited strong growth-inhibitory activities against imatinib-resistant GIST and SM cells, and a significantly higher anti-cancer effect than carboplatin/etoposide against SCLC cells. Combination of NN2101-DM1 with imatinib in imatinib-sensitive GIST cells induced complete remission in mouse xenograft models, suggesting its potential as a therapeutic agent for wild-type and mutant c-Kit-positive cancers.
MOLECULAR ONCOLOGY
(2022)
Article
Oncology
Mengyuan Liu, Mark S. Etherington, Andrew Hanna, Benjamin D. Medina, Gerardo A. Vitiello, Timothy G. Bowler, Nesteene J. Param, Lillian Levin, Ferdinand Rossi, Ronald P. DeMatteo
Summary: Type I IFNs play a role in tumor immunogenicity and response to therapy; oncogene signaling, like KIT, affects IFN-I signaling and regulates tumor MHC class I expression; enhancing the type I IFN response can partially compensate for the immunosuppressive effects of KIT inhibition in GIST.
CANCER IMMUNOLOGY RESEARCH
(2021)
Article
Oncology
Kwang-Hyeok Kim, Jisoo Park, Jin-Ock Kim, Han-Jik Ko, Sang Gyu Park
Summary: In this study, the authors developed 2G4 immunotoxins as an alternative therapeutic strategy for microtubule inhibitor-resistant cancer cells. The immunotoxins efficiently induced cytotoxicity in c-Kit-positive cells by inhibiting protein synthesis, leading to a significant inhibition of tumor growth in vivo.
ANTICANCER RESEARCH
(2022)
Article
Oncology
Jie Qi, Yue Shi, Yezhen Tan, Qi Zhang, Jianye Zhang, Jilu Wang, Cong Huang, Weimin Ci
Summary: This study analyzed the changes of DNA 5-hydroxymethylcytosine (5hmC) in genitourinary cancers and found tissue-specific distribution of 5hmC as well as regional gain and global loss of 5hmC in these cancers. The genes with gain of 5hmC were functionally enriched in stemness and hypoxia, and associated with poor clinical prognosis. The study also discovered that an oxidation-resistant vitamin C derivative restored 5hmC and induced apoptosis in cancer stem cell-like cells.
CLINICAL EPIGENETICS
(2022)
Review
Oncology
Medi Kori, Kazim Yalcin Arga
Summary: As the research shows, infections caused by certain viruses contribute to the development of cancer. However, prevention and treatment strategies for viral cancers have not made significant progress in the last century. This review aims to shed light on protein biomarkers of oncogenic viruses and evaluate their potential clinical applications.
EXPERT REVIEW OF ANTICANCER THERAPY
(2022)
Article
Oncology
Cissimol P. Joseph, Sarah N. Abaricia, Michelle A. Angelis, Kathleen Polson, Robin L. Jones, Yoon-Koo Kang, Richard F. Riedel, Patrick Schoffski, Cesar Serrano, Jonathan Trent, Eric D. Tetzlaff, Tuan Dong Si, Teresa Zhou, Ashley Doyle, Sebastian Bauer, Maria Roche, Tracy Havnaer
Summary: Avapritinib, a novel inhibitor approved for U/M GISTs, showed common treatment-related AEs including nausea, fatigue, and anemia. Cognitive effects were observed in a significant percentage of patients, particularly in older patients, but improved faster with dose modification. Utilizing tolerability-guided dose modification may be an effective strategy in managing AEs and maintaining patients on avapritinib treatment.
Article
Oncology
Suzanne George, Robin L. Jones, Sebastian Bauer, Yoon-Koo Kang, Patrick Schoffski, Ferry Eskens, Olivier Mir, Phillipe A. Cassier, Cesar Serrano, William D. Tap, Jonathan Trent, Piotr Rutkowski, Shreyaskumar Patel, Sant P. Chawla, Eval Meiri, Michael Gordon, Teresa Zhou, Maria Roche, Micahel C. Heinrich, Margaret von Mehren
Summary: The study showed that avapritinib, as a fourth-line or later treatment in patients with GIST harboring KIT or PDGFRA mutations, has manageable toxicity with meaningful clinical activity in some patients.
Article
Oncology
Crystal Seldon, Gautam Shrivastava, Melanie Fernandez, John Jarboe, Sheila Conway, Juan Pretell, Laura Freedman, Aaron Wolfson, Wei Zhao, Deukwoo Kwon, Andrew Rosenberg, Ty Subhawong, Jonathan Trent, Raphael Yechieli
Summary: Combined chemotherapy and radiation for high-grade soft tissue sarcomas have been shown to improve treatment response, with higher rates of pathologic necrosis correlating with better oncological outcomes.
Review
Oncology
Bernd Kasper, Annie Achee, Kathrin Schuster, Roger Wilson, Gerard van Oortmerssen, Rebecca A. Gladdy, Matthew L. Hemming, Paul Huang, Matthew Ingham, Robin L. Jones, Seth M. Pollack, Denise Reinke, Roberta Sanfilippo, Scott M. Schuetze, Neeta Somaiah, Brian A. Van Tine, Breelyn Wilky, Scott Okuno, Jonathan Trent
Summary: This paper summarizes the current state of treatments for leiomyosarcoma patients, highlighting knowledge gaps and unmet needs, and encourages the community to design innovative clinical trials and basic research to address these issues.
Article
Oncology
Suzanne George, Ping Chi, Michael C. Heinrich, Margaret von Mehren, Robin L. Jones, Kristen Ganjoo, Jonathan Trent, Hans Gelderblom, Albiruni A. Razak, Michael S. Gordon, Neeta Somaiah, Julia Jennings, Julie Meade, Kelvin Shi, Ying Su, Rodrigo Ruiz-Soto, Filip Janku
Summary: The study demonstrated that Ripretinib intrapatient dose escalation (IPDE) in GIST patients can provide continued clinical benefit across second, third, and later lines of therapy. Comparison of treatment-emergent adverse events (TEAEs) at different doses showed similar safety profiles.
EUROPEAN JOURNAL OF CANCER
(2021)
Article
Oncology
Joshua P. Kronenfeld, Jessica S. Crystal, Emily L. Ryon, Sina Yadegarynia, Celeste Chitters, Raphael Yechieli, Gina D'Amato, Andrew E. Rosenberg, Susan B. Kesmodel, Jonathan C. Trent, Neha Goel
Summary: Primary angiosarcoma of the breast (PAS) and radiation-associated angiosarcoma of the breast (RAAS) are rare sarcomas with incidences of 0.05% and 0.02%, respectively. Multimodal treatment with neoadjuvant chemotherapy, radiation therapy, surgery, and adjuvant chemotherapy can result in optimal clinical outcomes. However, further prospective, multi-institutional studies are needed to overcome the limitations associated with the low incidence of breast angiosarcoma.
Review
Oncology
Junaid Arshad, Philippos A. Costa, Priscila Barreto-Coelho, Brianna Nicole Valdes, Jonathan C. Trent
Summary: Gastrointestinal stromal tumors (GIST) are the most common type of gastrointestinal sarcomas, and recent treatment advancements have significantly improved patient survival rates. However, metastatic GIST patients may require multiple lines of treatment, and the potential role of immunotherapies in enhancing current therapies needs further exploration through in-depth research.
Article
Oncology
Andrea P. Espejo-Freire, Andrew Elliott, Andrew Rosenberg, Philippos Apolinario Costa, Priscila Barreto-Coelho, Emily Jonczak, Gina D'Amato, Ty Subhawong, Junaid Arshad, Julio A. Diaz-Perez, William M. Korn, Matthew J. Oberley, Daniel Magee, Don Dizon, Margaret von Mehren, Moh'd M. Khushman, Atif Mahmoud Hussein, Kirsten Leu, Jonathan C. Trent
Summary: Angiosarcomas are rare and highly aggressive sarcomas with limited treatment options. Genomic sequencing has identified recurrent genetic abnormalities in different primary sites of AS, which can help in designing and optimizing therapeutic strategies. The study analyzed NGS and WTS data in a cohort of 143 cases, revealing distinct genomic biology according to the AS primary site.
Article
Immunology
Michael Kueht, Ahmad Kharsa, Muhammad Mujtaba, Rupak Kulkarni, Rachel Britt, A. Scott Lea, Ghani Hafiz, Jeffery Fair, David Reynoso
Summary: This study aims to demonstrate the association of an institutional integrated stewardship program with C. difficile testing practices after abdominal solid organ transplantation. The results show that the program significantly decreased the number of C. difficile tests, reduced the cost of inpatient treatment and days of therapy, without affecting the rate of negative testing.
TRANSPLANTATION PROCEEDINGS
(2022)
Article
Medicine, General & Internal
John W. Davis, Beilin Wang, Ewa Tomczak, Chia Chi-Fu, Wissam Harmouch, David Reynoso, Philip Keiser, Miguel Mauricio Cabada
Summary: The study aimed to develop a model to predict the likelihood of COVID-19 patients progressing to severe hypoxemic respiratory failure using demographic and clinical data collected upon admission. The results showed that lactate dehydrogenase, Quick Sequential Organ Failure Assessment score, and neutrophil to lymphocyte ratio were significant predictors of severe disease. The model demonstrated high accuracy in predicting the deterioration of COVID-19.
Letter
Cardiac & Cardiovascular Systems
Ravi Thakker, Deaa Abu Jazar, Ayman Elbadawi, David Reynoso, Lindsay Sonstein, Robert J. Widmer, Hani Jneid, Khaled Chatila, Wissam Khalife
JOURNAL OF THE AMERICAN HEART ASSOCIATION
(2022)
Article
Oncology
Michael J. Wagner, Cassandra Hennessy, Alicia Beeghly, Benjamin French, Dimpy P. Shah, Sarah Croessmann, Diana Vilar-Compte, Erika Ruiz-Garcia, Matthew Ingham, Gary K. Schwartz, Corrie A. Painter, Rashmi Chugh, Leslie Fecher, Cathleen Park, Olga Zamulko, Jonathan C. Trent, Vivek Subbiah, Ali Raza Khaki, Lisa Tachiki, Elizabeth S. Nakasone, Elizabeth T. Loggers, Chris Labaki, Renee Maria Saliby, Rana R. McKay, Archana Ajmera, Elizabeth A. Griffiths, Igor Puzanov, William D. Tap, Clara Hwang, Sachin R. Jhawar, Brandon Hayes-Lattin, Elizabeth Wulff-Burchfield, Anup Kasi, Daniel Y. Reuben, Gayathri Nagaraj, Monika Joshi, Hyma Polimera, Amit A. Kulkarni, Khashayar Esfahani, Daniel H. Kwon, Luca Paoluzzi, Mehmet A. Bilen, Eric B. Durbin, Petros Grivas, Jeremy L. Warner, Elizabeth J. Davis
Summary: Patients with sarcoma have a higher risk of developing complications from COVID-19, and patients with bone sarcoma may be at a greater risk of death from COVID-19. Older age, poor performance status, and lung metastases are risk factors for more severe COVID-19.
Article
Oncology
Priscila Barreto-Coelho, Andrew Rosenberg, Ty Subhawong, Philippos Costa, Andrea P. Espejo-Freire, Steven Bialick, Emily Jonczak, Jonathan C. Trent, Gina Z. D'Amato
JCO PRECISION ONCOLOGY
(2022)
Article
Oncology
Ty K. Subhawong, Katharina Feister, Kevin Sweet, Noam Alperin, Deukwoo Kwon, Andrew Rosenberg, Jonathan Trent, Breelyn A. Wilky
Summary: The study demonstrates that MRI volumetric and image texture analysis can correlate with treatment-induced biologic changes in desmoid fibromatosis (DF) earlier than conventional response criteria, providing a more accurate and comprehensive analysis of DF behavior and therapeutic response.
RADIOLOGY-IMAGING CANCER
(2021)
Article
Oncology
Chao Liu, Kai Wang, Luyuan Li, Qingquan Lv, Yumei Liu, Tian Hu, Jonathan C. Trent, Bing Sun, Qinyong Hu
Summary: The study found distinct clinical features in COVID-19 patients with cancer compared to those without cancer, including leukopenia, elevated hs-CRP, and procalcitonin, as well as poorer outcomes in cancer patients with critical COVID-19. Recent cancer diagnosis and anti-tumor treatment within 3 months of COVID-19 diagnosis were associated with inferior survival in the cancer cohort.
